

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Currently amended claims showing deletions by ~~striking through~~ and additions by underlining)

In the Claims

1. (currently amended) A method of determining the ability of a compound to ~~both~~ bind selectively to a somatostatin type-5 receptor and inhibit amylin release from amylin-secreting pancreas cells, said method comprising:

obtaining a preparation which contains somatostatin type-5 receptor;

incubating said preparation, said compound, and a somatostatin type-5 receptor ligand, at least one of said ligand and said compound being detectably labeled;

determining the ability of said compound to compete against said ligand for binding to said somatostatin type-5 receptor;

if and only if said compound is determined to be able to bind to a somatostatin type-5 receptor and to exhibit a Ki value to said somatostatin type-5 receptor at least 2.5 times greater than the Ki value of said compound to a somatostatin type-2 receptor, obtaining amylin-secreting pancreatic cells;

incubating said compound, said pancreatic cells, and an amylin release stimulator under conditions in which said amylin release stimulator would induce release of amylin from said pancreatic cells; and

determining the ability of said compound to inhibit amylin release.

2. (original) A method of claim 1, wherein said preparation is a cell preparation.

3. (original) A method of claim 1, wherein said preparation is a membrane preparation.

4. (original) A method of claim 1, wherein said preparation is derived from a rodent olfactory bulb.

5. (original) A method of claim 1, wherein said preparation is derived from CHO-K1 cells transfected with the human somatostatin type-5 receptor.

6. (original) A method of claim 3, wherein said preparation is derived from a rodent olfactory bulb.

7. (original) A method of claim 3, wherein said preparation is derived from CHO-K1 cells transfected with the human somatostatin type-5 receptor.

8. (original) A method of claim 1, wherein said ligand is detectably labeled.

9. (original). A method of claim 3, wherein said ligand is detectably labeled.

10. (original) A method of claim 1, wherein said pancreatic cells are pancreatic islet cells.

11. (original) A method of claim 10, wherein said pancreatic islet cells are β cells.

12. (original) A method of claim 1, wherein said pancreatic cells are amylinoma cells.

13. (original) A method of claim 1, wherein said pancreatic cells are cells in an isolated rodent pancreas.

14. (original) A method of claim 1, wherein said pancreatic cells are RINm5f cells.

15. (original) A method of claim 3, wherein said pancreatic cells are pancreatic islet cells.

16. (original) A method of claim 15, wherein said pancreatic islet cells are β cells.

17. (original) A method of claim 3, wherein said pancreatic cells are amylinoma cells.

18. (original). A method of claim 3, wherein said pancreatic cells are cells in an isolated rodent pancreas.

19. (original). A method of claim 3, wherein said pancreatic cells are RINm5f cells.

20-22. (canceled)